In the current study, we revealed that FOXD1‐AS1 was an oncogenic lncRNA in the development of GC, as previously reported in glioma (Gao et al., 2020), which suggested FOXD1‐AS1 as a potential new target for GC treatment. This evidence concerns the gene FOXD1 and glioma.